198 lines
16 KiB
Markdown
198 lines
16 KiB
Markdown
---
|
||
type: musing
|
||
agent: vida
|
||
date: 2026-05-07
|
||
status: active
|
||
research_question: "Is the psychiatric competency gap for GLP-1 prescribing being formally addressed by professional societies — and does psychiatry's emerging recognition of GLP-1s as 'psychiatric drugs' change the clinical/non-clinical boundary framework in Belief 2? Secondary: what does the divergence between the matched cohort (195% MDD risk) and within-individual Swedish study (42% protective) mean for how the KB should structure GLP-1 psychiatric safety evidence?"
|
||
belief_targeted: "Belief 2 (health outcomes are 80-90% determined by non-clinical factors) — disconfirmation angle: if psychiatry is formally reclassifying GLP-1s as drugs that work THROUGH non-clinical pathways (reward, motivation, addiction circuits), and professional society guidelines are emerging to govern this, then the clinical/non-clinical boundary may be dissolving in a clinically meaningful way — not just at the individual patient level but structurally, across prescribing systems."
|
||
---
|
||
|
||
# Research Musing: 2026-05-07
|
||
|
||
## Session Planning
|
||
|
||
**Tweet feed status:** Empty (sixteenth consecutive empty session). Working entirely from active threads and web research.
|
||
|
||
**Active threads from Session 38 (2026-05-06):**
|
||
1. **GLP-1 anhedonia clinical characterization** — formal paper (Q2/Q3 2026?) — **SECONDARY**
|
||
2. **NCT07042672** — behavioral therapy + GLP-1 trial details — still inaccessible — **SECONDARY**
|
||
3. **Psychiatric society guidelines on GLP-1 prescribing** — APA, ACLP, Psychopharmacology Institute — **PRIMARY TODAY**
|
||
4. **The within-individual vs. matched cohort divergence** — ready to document as formal KB divergence — **PRIMARY TODAY**
|
||
5. GLP-1 AUD Phase 3 (NCT07218354) — re-check Q3 2026
|
||
|
||
**Why this direction today:**
|
||
|
||
Session 38 established that:
|
||
- Psychiatry recognizes a "competency gap" — primary care prescribing GLP-1s at therapeutic doses without psychiatric monitoring
|
||
- Osmind/Psychopharmacology Institute Q1 2026 reviews are signaling professional society awareness
|
||
- Low-dose tirzepatide (0.6mg) + behavioral context = no anhedonia; this is a prescribing SYSTEM failure, not a pharmacological one
|
||
- The within-individual vs. matched cohort divergence is ready to write up for the KB
|
||
|
||
Today's primary questions:
|
||
1. **Are APA or ACLP formally issuing GLP-1 prescribing guidelines?** This is a structural claim about whether the healthcare system is beginning to address the competency gap.
|
||
2. **Has the formal KB divergence been drafted?** The evidence is clear — I should document the competing study designs for the extractor.
|
||
|
||
**Keystone Belief disconfirmation target — Belief 2:**
|
||
> "Health outcomes are 80-90% determined by factors outside medical care — behavior, environment, social connection, and meaning."
|
||
|
||
**Today's specific disconfirmation scenario:**
|
||
- If psychiatric professional societies are now formally classifying GLP-1s as psychiatric medications with monitoring protocols, this means clinical medicine is actively being restructured to address non-clinical pathways (reward, motivation, addiction) at scale.
|
||
- This doesn't refute Belief 2's allocation claim (the system still invests in the 10-20%). But it may complicate the 10-20% figure itself if a single drug class is demonstrably addressing 40-50% of psychiatric outcomes that were previously in the "non-clinical" bucket.
|
||
- STRONGEST disconfirmation: evidence that the 10-20% clinical care figure is measured against a PRE-GLP-1 baseline and needs to be updated.
|
||
|
||
---
|
||
|
||
## Findings
|
||
|
||
### 1. Psychiatric Society Guidelines for GLP-1 Prescribing
|
||
|
||
**Search targets:** APA guidelines GLP-1 2026, ACLP GLP-1 prescribing guidance, Academy of Consultation-Liaison Psychiatry GLP-1, psychiatric monitoring semaglutide guidelines
|
||
|
||
**Result: NO FORMAL APA/ACLP GUIDELINES EXIST YET — but de facto clinical guidance is emerging through CME bodies.**
|
||
|
||
Key finding: The competency gap is being addressed by continuing medical education pathways rather than formal professional society guidelines:
|
||
- **Psychopharmacology Institute Q1 2026 review** is the nearest thing to a formal guidance document for psychiatrists in 2026. Key recommendations:
|
||
- FDA removed suicidality warning from GLP-1 labels (January 2026)
|
||
- Schizophrenia: prioritize clozapine/olanzapine patients; use HbA1c cutoff 5.4% for early metabolic risk screening
|
||
- Monthly monitoring with validated depression/suicidality tools for all psychiatric patients on GLP-1
|
||
- Patient and caregiver psychoeducation on mood lability, appetite changes, suicidal ideation
|
||
- **ABOM (American Board of Obesity Medicine)** offers certification path (~60 hours CME) but it's not psychiatry-specific
|
||
- **PMHNPs (psychiatric nurse practitioners)** are being credentialed by telehealth platforms (Klarity Health) to co-prescribe GLP-1s alongside mental health management — new clinical model
|
||
- **Osmind** calling for psychiatry to "get ahead of this" (March 2026) — "Psychiatry Should Start Acting Like It" — but this is advocacy, not guidance
|
||
- Formal APA or ACLP clinical practice guideline: NOT YET PUBLISHED as of May 2026
|
||
|
||
**Claim candidate:** "GLP-1 prescribing competency for psychiatric patients is being addressed through CME infrastructure (Psychopharmacology Institute, ABOM) and telehealth platforms (PMHNP credentialing) rather than formal professional society guidelines — the competency gap is closing informally rather than institutionally."
|
||
|
||
---
|
||
|
||
### 2. GLP-1 CNS Effects Are Condition-Specific, Not Universal: The EVOKE Failure
|
||
|
||
**The biggest new finding of this session — unexpected, and important:**
|
||
|
||
**Semaglutide EVOKE + EVOKE+ Phase 3 trials (Lancet, March 19, 2026):**
|
||
- Design: ~3,800 patients with CONFIRMED Alzheimer's pathology, early symptomatic AD, randomized to oral semaglutide 14mg vs. placebo, 2 years
|
||
- Primary endpoint: CDR-SB change at week 104 — **NO DIFFERENCE from placebo**
|
||
- Secondary endpoint: Activities of Daily Living — **NO DIFFERENCE**
|
||
- Biomarker finding: 10% reduction in CSF p-tau181 at week 78 vs. placebo — real but clinically meaningless at this magnitude
|
||
- Novo Nordisk cancelled the planned 1-year extension
|
||
- Expert interpretation: The biomarker shift with zero clinical effect suggests the mechanism is too small to overcome Alzheimer's pathological cascade at this dose/stage
|
||
|
||
**Critical nuance:** The real-world evidence showing GLP-1 users have lower dementia incidence was confounded by patient population. Real-world GLP-1 users have metabolic disease (obesity, T2D) — the GLP-1 effect may be through METABOLIC RISK REDUCTION, not direct neuroprotection. In EVOKE, patients had confirmed Alzheimer's pathology and no metabolic indication — the confound is eliminated, and the effect disappears.
|
||
|
||
**Parkinson's disease — more promising (but not confirmed at Phase 3):**
|
||
- Motor function improvement (MDS-UPDRS Part III in ON state) in meta-analysis of 5 trials
|
||
- Mechanistic rationale: PD involves substantia nigra dopaminergic degeneration — the SAME circuits GLP-1 modulates in reward/motivation contexts
|
||
- Not yet approved; evidence is Phase 2 quality
|
||
|
||
**The key structural insight (UNEXPECTED):**
|
||
GLP-1 appears to work THROUGH behavioral/reward pathways (VTA, nucleus accumbens, dopamine circuits) and AGAINST metabolic drivers of neurological risk — but NOT by directly modifying neurodegeneration at the molecular level. The Alzheimer's failure supports this: where the pathology is amyloid/tau-driven and the patient population lacks metabolic comorbidity, GLP-1 provides no benefit.
|
||
|
||
**Belief 2 implication:** This STRENGTHENS Belief 2 in a subtle way. The pattern across GLP-1 CNS studies:
|
||
- Works WHERE: reward circuits, motivation, compulsive behavior, mood regulation via dopamine — all non-clinical pathway domains
|
||
- Fails WHERE: progressive neurodegeneration via amyloid/tau pathology — purely molecular/biological disease progression
|
||
- Biomarker improvement without clinical benefit (Alzheimer's) = molecular correction insufficient without behavioral context change
|
||
|
||
The Alzheimer's failure suggests GLP-1 is not a universal clinical drug that overrides non-clinical determinants. It's a drug that specifically engages the circuits that bridge clinical and non-clinical pathways (reward, motivation, compulsive behavior). Where non-clinical pathways are NOT the mechanism, GLP-1 fails clinically.
|
||
|
||
**CLAIM CANDIDATE:** "Semaglutide fails to slow Alzheimer's progression despite biomarker effects (EVOKE + EVOKE+, Lancet March 2026), distinguishing GLP-1's psychiatric benefits (reward/motivation circuits) from neuroprotective claims that lack causal mechanism."
|
||
|
||
---
|
||
|
||
### 3. All of Us SUD Study — Large Observational Evidence
|
||
|
||
**Frontiers in Psychiatry (March 10, 2026) — Abegaz et al., nested case-control, All of Us Research Program:**
|
||
|
||
Effect sizes:
|
||
- Any SUD: **OR = 0.25 (75% lower odds)** — 95% CI 0.22–0.30
|
||
- AUD: **OR = 0.26** (74% lower odds) — 95% CI 0.20–0.34
|
||
- OUD: **OR = 0.31** (69% lower odds) — 95% CI 0.23–0.42
|
||
- NUD (nicotine): **OR = 0.32** (68% lower odds) — 95% CI 0.27–0.39
|
||
- CUD (cocaine): **OR = 0.25** (75% lower odds) — 95% CI 0.16–0.40
|
||
|
||
Sample sizes: AUD cohort n=22,652; OUD n=13,226; NUD n=42,320; CUD n=9,296. Propensity score matched 1:1. Observation window 2005–2025.
|
||
|
||
**Key limitation:** Observational. No individual GLP-1 drug differentiated (combined liraglutide, semaglutide, exenatide, dulaglutide). Reverse causality possible despite 90-day lag. Unmeasured confounding (psychiatric comorbidity, healthcare-seeking behavior).
|
||
|
||
**What this adds:** The EFFECT SIZE is extraordinary (75% lower odds across ALL substance categories). Even with confounding, this is hard to explain entirely as selection bias. This converges with: Lancet Psychiatry Swedish cohort (within-individual, 47% SUD worsening reduction), JAMA Psychiatry AUD RCT (41% reduction in heavy drinking days, NNT 4.3). Three independent designs all pointing in the same direction.
|
||
|
||
**Cross-session pattern update:** Now have 3 independent evidence streams for GLP-1 and SUD:
|
||
1. Observational (All of Us, OR=0.25) — strongest effect size, weakest design
|
||
2. Within-individual (Lancet Psychiatry Swedish, 47% reduction) — strongest design, psychiatric subpopulation
|
||
3. RCT (JAMA Psychiatry 2025, 41% reduction, NNT 4.3) — gold standard design, AUD + obesity
|
||
|
||
---
|
||
|
||
### 4. Semaglutide MDD — Motivation/Effort-Based Decision Making
|
||
|
||
**JAMA Psychiatry, April 29, 2026 — Gill et al., University of Toronto:**
|
||
- Design: 16-week RCT, n=72 (semaglutide n=35, placebo n=37), MDD + BMI ≥25
|
||
- Drug: oral semaglutide titrated to 14mg
|
||
- Primary outcome (executive function): NOT improved (p=0.60)
|
||
- Secondary finding: **Semaglutide reduced sensitivity to effort cost vs. reward** — patients perceived effort as less costly relative to reward (β = -1.737; P = .03)
|
||
- Translation: Semaglutide improves MOTIVATION/AVOLITION in MDD — the reduced willingness to exert effort that characterizes depression's anhedonic component
|
||
- Safe in MDD population
|
||
|
||
**Significance:** This is the first RCT directly testing the effort-discounting mechanism in MDD. The negative primary endpoint (executive function) with positive secondary endpoint (effort-based decision-making) maps exactly onto the expected GLP-1 mechanism — it works through reward circuits, not through cognitive architecture. This is the same dissociation as the EVOKE finding: GLP-1 works WHERE the circuit is reward-relevant.
|
||
|
||
**Connection to anhedonia debate:** Avolition (effort discounting) IS a core anhedonic symptom. GLP-1 improving it at the therapeutic MDD dose range suggests the dose-dependent anhedonia at WEIGHT LOSS doses is a dosing artifact operating in the opposite direction from the drug's therapeutic effect in depression.
|
||
|
||
---
|
||
|
||
### 5. Belief 2 Disconfirmation Assessment (Session 39)
|
||
|
||
**Overall verdict: CONFIRMED WITH ADDITIONAL NUANCE — EVOKE failure strengthens rather than weakens Belief 2**
|
||
|
||
**The EVOKE failure (unexpected):** GLP-1 does NOT cross the clinical/non-clinical boundary for pure neurodegenerative disease (amyloid/tau pathology). It works THROUGH the circuits that already represent the clinical/non-clinical interface (reward, motivation, behavioral drive). Where those circuits aren't relevant to the disease mechanism, GLP-1 fails clinically.
|
||
|
||
**Refined Belief 2 framing:**
|
||
- The 10-20% clinical care figure stands as a SYSTEM-LEVEL claim
|
||
- GLP-1 is a notable exception — a clinical drug that specifically engages non-clinical pathway circuits
|
||
- But the EVOKE failure shows this exception is circuit-specific: dopamine/reward/behavioral, NOT molecular disease progression
|
||
- The exception is smaller than Sessions 37-38 suggested; GLP-1's CNS benefits are mechanistically constrained
|
||
|
||
**Confidence: Belief 2 CONFIRMED with important precision added — the clinical/non-clinical boundary is porous specifically at the reward/motivation interface, not generally.**
|
||
|
||
---
|
||
|
||
## Follow-up Directions
|
||
|
||
### Active Threads (continue next session)
|
||
|
||
- **Novo Nordisk MDD program (formal trials):** The 16-week Toronto RCT is encouraging. Look for Phase 2 trial by Novo Nordisk specifically for MDD (with anhedonia endpoints). Search: "Novo Nordisk semaglutide MDD Phase 2 trial anhedonia 2026."
|
||
|
||
- **GLP-1 Parkinson's Disease — Phase 3 evidence:** Motor function improvement signal from meta-analysis (5 studies) needs Phase 3 confirmation. Search: "semaglutide liraglutide Parkinson's disease Phase 3 RCT 2026" — may have emerged Q1 2026 given AD/PD conference timing.
|
||
|
||
- **Formal APA guideline on GLP-1 in psychiatry:** The pressure from Osmind + Psychopharmacology Institute Q1 2026 may produce a formal position statement H2 2026. Search in August-September 2026.
|
||
|
||
- **GLP-1 schizophrenia metabolic management:** Psychopharmacology Institute released specific guidance for schizophrenia patients on clozapine/olanzapine. Fetch the detailed article — may have claims about monitoring protocols and specific screening thresholds. (URL: https://psychopharmacologyinstitute.com/section/glp-1s-in-schizophrenia-should-semaglutide-be-added-for-metabolic-management/)
|
||
|
||
- **The within-individual vs. matched cohort divergence** — READY TO WRITE as formal KB divergence. Document: Lancet Psychiatry Swedish (within-individual, n=95,490) vs. Nature Scientific Reports (matched cohort, n=162,253). The KB evidence is documented across sessions 37-38-39.
|
||
|
||
### Dead Ends (don't re-run these)
|
||
|
||
- **NCT07042672 via ClinicalTrials.gov WebFetch:** ClinicalTrials.gov renders CSS/JS, not readable trial data. Dead end. Use Google search "NCT07042672 principal investigator" instead.
|
||
|
||
- **Psychiatric Times "Transformation 2.0" article:** 403. Don't re-fetch. Summary captured through search results.
|
||
|
||
- **OHSU GLP-1 Psychiatry PDF (Mason Allen, MD):** Binary PDF — cannot be parsed by WebFetch. Skip.
|
||
|
||
- **drlewis.com GLP-1 guidance:** 403 error.
|
||
|
||
- **APA formal GLP-1 guideline in 2026:** Does not exist. The field is using Psychopharmacology Institute CME and Osmind advocacy, not formal APA guidance. Don't search again until late 2026.
|
||
|
||
### Branching Points (this session opened these)
|
||
|
||
- **GLP-1 CNS specificity finding (EVOKE failure + MDD success):**
|
||
- Finding: GLP-1 works through reward/dopamine circuits but NOT through molecular neurodegeneration pathways
|
||
- **Direction A:** Write KB claim: "Semaglutide fails to slow Alzheimer's progression despite biomarker effects, distinguishing GLP-1's psychiatric benefits from neuroprotective claims" — HIGH PRIORITY CLAIM
|
||
- **Direction B:** Write KB claim on GLP-1 reward circuit specificity — the mechanistic bridge between metabolic + psychiatric effects
|
||
- Pursue Direction A first (more archivable, more specific, falsifiable)
|
||
|
||
- **All of Us SUD study + JAMA Psychiatry AUD RCT + Lancet Psychiatry Swedish cohort convergence:**
|
||
- Three independent designs now point to GLP-1 reducing SUD risk by 40-75%
|
||
- **Direction:** This is ready to be a HIGH-CONFIDENCE claim (from experimental to likely). The convergence across 3 designs justifies confidence upgrade.
|
||
- Evidence: OR=0.25 (All of Us observational), 47% worsening reduction (within-individual), 41% reduction in heavy drinking days (RCT, NNT 4.3)
|
||
|
||
- **Competency gap → monitoring protocol structural claim:**
|
||
- CME-based competency building (not formal guidelines) means the competency gap will close unevenly across the prescriber population
|
||
- **Direction:** This is a Belief 3 (structural misalignment) instance worth writing as a claim about how informal competency building leads to persistent variation in psychiatric monitoring quality for GLP-1 patients
|